Opinion of the Transparency Council – sirolimusum
At its meeting on 10 February 2025, the Transparency Council adopted opinion No. 26/2025 on the reimbursement of medicines containing the active substance sirolimusum for indications, dosages or administration methods other than those specified in the Summary of Product Characteristics, i.e. tuberous sclerosis, lymphangioleiomyomatosis, epithelioid cell tumor